Bluebird, Celgene myeloma treatment impresses in tiny study

Bluebird, Celgene myeloma treatment impresses in tiny study


Patients who previously were not helped by repeated treatments for multiple myeloma showed strong benefits from a new type of therapy in a small study, and with no worrisome side effects, drugmaker Bluebird Bio Inc said on Wednesday. The Phase 1 study enrolled patients who had basically run out of options for the blood cancer, after failing on average six previous rounds of treatment, including stem cell transplants.



from Biotech News